| Dr Laura Kate Tom, MD | |
|
106 Irving St Nw Ste 3400, Washington, DC 20010 | |
| (202) 877-3300 | |
| Not Available |
| Full Name | Dr Laura Kate Tom |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 13 Years |
| Location | 106 Irving St Nw Ste 3400, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053610832 | NPI | - | NPPES |
| 1053610832 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | MD046456 (District Of Columbia) | Primary |
| 208200000X | Plastic Surgery | MD60487179 (Washington) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medstar Washington Hospital Center | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medstar Medical Group Ii Llc | 0547413825 | 1776 |
News Archive
A new study has found that an all-day, extended-release stimulant for treating attention-deficit hyperactivity disorder (ADHD) remains effective for up to two years without significant side effects.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers.
Short-term exposure to fine particulate matter - the microscopic particles that pollute the air - increased hospital admissions for cardiovascular and respiratory disease among Medicare participants, according to a study of 204 U.S. urban counties conducted by researchers at the Johns Hopkins Bloomberg School of Public Health and Yale University's environment school.
Severely ill patients with anxiety disorders or Obsessive-Compulsive Disorder undergoing neurosurgical treatment risk serious complications.
› Verified 6 days ago
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000415 |
News Archive
A new study has found that an all-day, extended-release stimulant for treating attention-deficit hyperactivity disorder (ADHD) remains effective for up to two years without significant side effects.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers.
Short-term exposure to fine particulate matter - the microscopic particles that pollute the air - increased hospital admissions for cardiovascular and respiratory disease among Medicare participants, according to a study of 204 U.S. urban counties conducted by researchers at the Johns Hopkins Bloomberg School of Public Health and Yale University's environment school.
Severely ill patients with anxiety disorders or Obsessive-Compulsive Disorder undergoing neurosurgical treatment risk serious complications.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura Kate Tom, MD 106 Irving St Nw Ste 3400, Washington, DC 20010-2965 Ph: (202) 877-3300 | Dr Laura Kate Tom, MD 106 Irving St Nw Ste 3400, Washington, DC 20010 Ph: (202) 877-3300 |
News Archive
A new study has found that an all-day, extended-release stimulant for treating attention-deficit hyperactivity disorder (ADHD) remains effective for up to two years without significant side effects.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers.
Short-term exposure to fine particulate matter - the microscopic particles that pollute the air - increased hospital admissions for cardiovascular and respiratory disease among Medicare participants, according to a study of 204 U.S. urban counties conducted by researchers at the Johns Hopkins Bloomberg School of Public Health and Yale University's environment school.
Severely ill patients with anxiety disorders or Obsessive-Compulsive Disorder undergoing neurosurgical treatment risk serious complications.
› Verified 6 days ago
Dr. Steven Paul Davison, MD, DDS, FACS Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3301 New Mexico Ave Nw, Suite 236, Washington, DC 20016 Phone: 202-966-9590 Fax: 202-966-9596 | |
Dr. Praful Maruti Ramineni, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2440 M St Nw, Suite 200, Washington, DC 20037 Phone: 202-785-4187 Fax: 202-785-1370 | |
Dr. Karen Kim Evans, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-9686 Fax: 866-990-5515 | |
Dr. Bharat Gubbi Ranganath, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 M St Nw Fl 6, Washington, DC 20037 Phone: 202-741-3240 | |
Pearl Ann Theresa Brown, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 21 7th St Se, Washington, DC 20003 Phone: 202-758-7577 | |
Dr. Lauren Marie Patrick, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 50 Irving St Nw, Washington, DC 20422 Phone: 202-745-8000 |